# Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy

> **NCT05167721** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 71 (actual)

## Conditions studied

- Multiple System Atrophy

## Interventions

- **BIOLOGICAL:** Autologous Mesenchymal Stem Cells
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05167721
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-15
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05167721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05167721, "Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05167721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*